- Active not recruitingPHASE3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This study looks at a new drug, tafasitamab, alongside standard treatments for follicular lymphoma and marginal zone lymphoma that have come back or not responded well. It aims to see if adding this new drug works better than the usual treatment alone.
For: Follicular Lymphoma · Marginal Zone LymphomaUnited States · Australia · Austria - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
For: Follicular Lymphoma (FL)United States · Australia · Belgium - Active not recruitingPHASE3
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients
This study compares two treatments for a type of slow-growing lymphoma called Splenic Marginal Zone Lymphoma (SMZL). It looks at whether a combination of two drugs, rituximab and zanubrutinib, works better and is as safe as rituximab alone for patients needing their first treatment.
For: Splenic Marginal Zone LymphomaAustria · France · Italy - Active not recruitingPHASE3
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
This study looks at new treatments for Mantle Cell Lymphoma in adults who can't have a stem cell transplant. It compares two drug combinations to see which works better and is safer.
For: Mantle Cell Lymphoma; Non-Hodgkin LymphomaUnited States · Australia · Austria - Active not recruitingPHASE3
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
This study is looking into a new drug, epcoritamab, for people with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It compares epcoritamab combined with standard treatment (R-CHOP) to R-CHOP alone, to see if the new combination works better.
For: Diffuse Large B-Cell LymphomaUnited States · Australia · Austria - RecruitingPHASE3
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
This study looks at a new drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares BGB-16673 to existing treatments in patients whose cancer has come back after trying two other types of drugs.
For: CLL · Chronic Lymphocytic LeukemiaUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
This study is looking into a new treatment, CC-99282, for non-Hodgkin lymphoma that has returned or not responded to other treatments. Researchers want to see how safe it is and how well it works, both by itself and with other lymphoma medicines.
For: Lymphoma, Non-HodgkinUnited States · Argentina · Austria - RecruitingPHASE1
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
This study is looking at a new medicine, LY4584180, for adults with certain blood cancers like lymphoma that have already been treated. We want to see if it's safe, how well it works, and how the body handles it. The study could last about 9 months or more.
For: Lymphoma, Non-Hodgkin's · Lymphoma, Diffuse Large B-Cell · Follicular LymphomaUnited States · France · Germany - Active not recruitingPHASE3
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
This study is for people in the UK with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has returned or not responded to previous treatments. It aims to see if adding an experimental drug, brentuximab vedotin, to two existing treatments (rituximab and lenalidomide) works better than the two existing treatments alone.
For: Diffuse Large B-cell LymphomaUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
This study looks at new drug combinations to treat B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. We want to see how safe and effective these new treatments are, especially when other treatments haven't worked.
For: B-cell Non-Hodgkin LymphomaUnited States · Belgium · Canada - Active not recruitingPHASE3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
This study is for adults with a type of blood cancer called follicular lymphoma, which has come back or isn't responding to treatment. It compares a new drug (Tazemetostat) with existing treatments to see if it's safe and helps people live longer without their cancer getting worse.
For: Relapsed/Refractory Follicular Lymphoma · Follicular Lymphoma · Refractory Follicular LymphomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
This study looks at a new drug, epcoritamab, combined with standard medicines (R2) for adults with follicular lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective this new combination is.
For: Follicular Lymphoma (FL)United States · Argentina · Australia - Active not recruitingPHASE3
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
This study is looking at a new medicine called acalabrutinib for chronic lymphocytic leukaemia (CLL). It compares acalabrutinib to usual treatments to see which works best for people whose CLL has come back or hasn't responded to previous treatment.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · Austria - Not yet recruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
This study looks at a new treatment called BMS-986353 for severe Systemic Sclerosis. It compares this new treatment with standard care to see if it's more effective and safe for people with this condition.
For: Systemic SclerosisUnited States · Belgium · Canada - Active not recruitingPHASE3
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
This study compares a new drug, zanubrutinib, with standard treatments (bendamustine and rituximab) for adults with previously untreated Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL). Researchers want to see which treatment works best to stop the cancer from getting worse.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
This study is looking into a new treatment, BMS-986458, both on its own and mixed with other anti-lymphoma medicines. It's for people in the UK with non-Hodgkin lymphoma that has come back or not responded to previous treatments. We want to see if it's safe and how well it works.
For: Relapsed/Refractory Non-Hodgkin LymphomaUnited States · Chile · China - RecruitingPHASE2
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
This study is testing a new treatment, rapcabtagene autoleucel, against an existing one, rituximab, for severe diffuse scleroderma. We want to see if the new treatment is safe and effective in helping people with this condition and improving their symptoms.
For: Scleroderma, DiffuseUnited States · Argentina · Australia - Active not recruitingPHASE2
Iptacopan in Patients With ANCA Associated Vasculitis
This study is looking at a new medicine called iptacopan for people with a rare condition called ANCA-associated vasculitis. It aims to see if iptacopan, when given with standard treatment, can help people get better and stay better, and if it's safe to use.
For: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated VasculitisUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
This study looks at a new combination of three chemotherapy-free drugs for people newly diagnosed with Mantle Cell Lymphoma. It aims to see if this treatment can clear the cancer and if some people can then stop treatment or use just one drug.
For: Mantle Cell Lymphoma (MCL)United States · Australia · Brazil - RecruitingPHASE3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
This study looks at new drug combinations for adults in the UK with a type of blood cancer called chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It compares new treatments with current ones to see which works best and is safest for patients whose cancer has come back or not responded to previous treatments.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Argentina · Australia - RecruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
For: DLBCL · Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
This study is looking at a new combination of treatments for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares a new drug called Nemtabrutinib with Venetoclax against a standard treatment, to see if the new combination is better at stopping the cancer from growing.
For: Leukemia, Lymphocytic, Chronic, B-Cell · Leukemia, Chronic Lymphocytic · Small-Cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
This study compares a new drug, odronextamab, with standard treatment for a type of lymphoma called DLBCL. It looks at how well they work with chemotherapy and their safety in adults who haven't been treated before, or whose lymphoma has come back.
For: Diffuse Large B-cell Lymphoma (DLBCL)United States · Australia · Austria - Active not recruitingPHASE3
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study looks at a new drug, Pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares Pirtobrutinib to standard treatments to see if it works better for those who have already tried other therapies.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Austria - Active not recruitingPHASE3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
This study is testing new treatments for two types of lymphoma, follicular and marginal zone lymphoma, when they have come back or not responded to previous treatment. It compares a drug called zanubrutinib combined with other medicines against a standard treatment to see which works best.
For: Relapsed/Refractory Follicular Lymphoma · Marginal Zone LymphomaUnited States · Argentina · Australia - RecruitingPHASE3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
This study is testing a new drug, odronextamab, for adults with follicular lymphoma that hasn't been treated before. It aims to find out if the drug is safe and how well it works compared to current standard treatments.
For: Follicular Lymphoma (FL)United States · Australia · Austria - RecruitingPHASE3
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
This study is testing a new combination of drugs, mosunetuzumab and lenalidomide, for follicular lymphoma. It compares this new treatment to standard chemotherapy for people who haven't had treatment before. The aim is to see if the new combination works better and is safe.
For: Follicular LymphomaAustria · Belgium · France - Active not recruitingPHASE2
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
This study looks at whether special treatments called immunotherapy can help people with a type of psychosis linked to the body's immune system. Researchers want to see if these treatments, intravenous immunoglobulin (IVIG) and rituximab, are safe and effective for this condition.
For: Psychosis · Autoimmune EncephalitisUnited Kingdom - RecruitingPHASE3
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
This study looks into a new treatment for follicular lymphoma and marginal zone lymphoma that have returned or didn't respond to previous treatments. It combines a new drug, odronextamab, with an existing one, lenalidomide, and compares it to a standard treatment.
For: Relapsed/Refractory Follicular Lymphoma · Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)United States · Australia · Austria - RecruitingPHASE2
Rescue of Nephrons With ALE.F02 (RENAL-F02)
This study looks into a new drug, ALE.F02, to see if it can help protect kidneys in people with a condition called ANCA-associated vasculitis (AAV). Researchers want to check if it's safe and effective at preserving kidney function.
For: Glomerulonephritis Rapidly ProgressiveCzechia · Denmark · France - Active not recruitingPHASE3
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
This study is looking at a new medicine called acalabrutinib. We want to see if adding it to standard treatment (bendamustine and rituximab, or BR) works better than standard treatment alone for people with a type of blood cancer called mantle cell lymphoma that hasn't been treated before.
For: Lymphoma, Mantle CellUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
This study compares two treatments for follicular lymphoma that has come back or not responded to previous treatments. It looks at a new drug, mosunetuzumab, combined with lenalidomide, versus a standard treatment, rituximab with lenalidomide, to see which works better and if they are safe.
For: Relapsed or Refractory Follicular LymphomaUnited States · Australia · Brazil - Active not recruitingPHASE3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This study looks at new treatments for Diffuse Large B-Cell Lymphoma (DLBCL) that has come back or not responded to previous treatment. It compares a new drug called epcoritamab with standard treatments to see which works best and is safest.
For: Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
This study looks at a new drug, Glofitamab, combined with standard treatment for a type of lymphoma called DLBCL. It aims to see if this new combination is safe and effective for patients who haven't been treated before and have a high-risk form of the disease.
For: LymphomaUnited States · Denmark · France - Active not recruitingPHASE2
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
This study is testing a new combination of medicines for older or less fit patients with a type of aggressive B-cell lymphoma who haven't had treatment before. The aim is to see if this new approach, called R-Pola-Glo, is safe and effective.
For: Lymphoma, Large B-Cell, DiffuseAustria · Germany - RecruitingPHASE2
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
This study is looking at a new treatment approach for a type of slow-growing (indolent) mantle cell lymphoma. It compares observing the condition with a combination of two drugs, zanubrutinib and rituximab, given for a set period, to see if earlier treatment is helpful.
For: Mantle Cell LymphomaUnited Kingdom - RecruitingPHASE2
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
This study is looking at a new type of treatment called liso-cel for adults with a brain lymphoma that can't have a stem cell transplant. It aims to see how safe and effective this new treatment is as the first treatment they receive.
For: LymphomaUnited States · France · Germany - Active not recruitingPHASE2
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
This study looks at a new combination of treatments for a type of lymphoma called diffuse large B-cell lymphoma. It combines standard chemotherapy with a newer drug called pembrolizumab to see if it works better for people whose lymphoma has come back or hasn't responded to previous treatment.
For: Diffuse Large B Cell LymphomaUnited Kingdom - Active not recruitingPHASE3
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
This study compares a new treatment, Pirtobrutinib, with standard drugs (Venetoclax and Rituximab) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who’ve had treatment before. Researchers want to see if the new combination works better and is safe.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
This study compares a new treatment, axicabtagene ciloleucel, with standard care for adults recently diagnosed with high-risk large B-cell lymphoma. It aims to see if the new treatment works better as a first treatment option.
For: High-risk Large B-cell Lymphoma (LBCL)United States · Australia · Austria - Active not recruitingPHASE3
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
This study is looking at a new treatment called glofitamab for a type of cancer called large B-cell lymphoma. It compares this new treatment, along with other medicines, against a standard treatment for people who haven't had treatment before.
For: Large B-Cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE4
Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft
This study looks at whether a single dose of rituximab can prevent serious health problems in adults who receive a kidney transplant. Specifically, it focuses on stopping a common virus (Epstein-Barr Virus) from causing issues in patients who haven't had it before, but whose donated kidney carries the virus.
For: Epstein-Barr Virus InfectionsFrance - Active not recruitingPHASE3
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study compares a new medicine, pirtobrutinib, with standard treatment (bendamustine and rituximab) for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see which is safer and works better.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Austria - Active not recruitingPHASE3
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
This study is looking at a new treatment combination for a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It combines a new drug, tafasitamab, and another drug, lenalidomide, with standard chemotherapy to see if it works better than chemotherapy alone.
For: Diffuse Large B-cell LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
This study looks at a new drug called acalabrutinib combined with standard chemotherapy (R-CHOP) for a type of blood cancer called Diffuse Large B-Cell Lymphoma, in people who haven't had treatment before. We want to see if this combination works better and is safe.
For: Diffuse Large B-Cell LymphomaUnited States · Australia · Austria - Active not recruitingPHASE3
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
This study looks at a new drug, Golcadomide, combined with standard chemotherapy (R-CHOP) for a type of blood cancer called large B-cell lymphoma. It wants to see if this new combination is safer and works better than R-CHOP alone for patients who haven't been treated before and have a high-risk form of the disease.
For: Large B-cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
This study looks at a new drug, epcoritamab, combined with other cancer medicines, for adults with Non-Hodgkin Lymphoma. It aims to see how safe these combinations are and if they help reduce the disease. Epcoritamab is given as an injection under the skin.
For: Non-Hodgkin LymphomaUnited States · China · Czechia - AuthorisedTherapeutic exploratory (Phase II)
Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG
This study looks at how safe and effective a medicine called rituximab is for people with certain mental health conditions like schizophrenia. It checks if repeated treatments help over a long time, comparing results to previous studies.
For: Schizophrenia spectrum disorder (SSD)Sweden - RecruitingPHASE3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
This study looks at a new drug, zilovertamab vedotin, combined with standard treatment for a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). Researchers want to see if this new combination helps people live longer without their cancer growing or spreading, compared to standard treatment alone.
For: Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE2
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
This study is testing a new combination of medicines, Copanlisib and Rituximab, for a type of blood cancer called Marginal Zone Lymphoma (MZL). It aims to see if this chemotherapy-free treatment is effective and has fewer side effects than current options, especially for older patients.
For: Marginal Zone LymphomaAustria · Germany